Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Prostaglandins Other Lipid Mediat ; 78(1-4): 3-13, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16303599

ABSTRACT

The prostanoid prostacyclin (PGI2) inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. Progression through G1 phase is regulated by the sequential activation of the G1 phase cyclin-dependent kinases (cdks). Recent studies have shown that PGI2-dependent activation of its receptor, IP, inhibits G1 phase progression by blocking the degradation of p27 and the activation of cyclin E-cdk2. High Density Lipoproteins (HDL) and its associated apolipoprotein, ApoE, also inhibit S phase entry of vascular SMCs, and the effects of HDL and ApoE are, at least in part, also mediated by the production of PGI2. The antimitogenic effects of hyaluronan may also be controlled by PGI2. This review summarizes the effects of PGI2 on the G1 phase cyclin-cdks and discusses the potential role of PGI2 as a common component of multiple extracellular signals that attenuate the proliferation of vascular SMCs.


Subject(s)
Cyclin-Dependent Kinases/metabolism , G1 Phase , Mitogens/antagonists & inhibitors , Mitosis/drug effects , Cyclin A/genetics , Estrogens/pharmacology , Humans , Hyaluronan Receptors/pharmacology , Hyaluronic Acid/pharmacology , Phosphorylation , S-Phase Kinase-Associated Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...